Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma

Completed

Conditions studied: Liver Cancer

In brief

The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with alpha-feto protein (AFP)

Key facts

Study ID

NCT00373347

Run by

Stanford University

People needed

573

Starts

2004-11-01

Expected to finish

2024-11-18

Last updated by the study team

2026-04-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients diagnosed with liver cancer based on biopsy or serum AFP level, associated with characteristic hypervascular liver tumors on triphasic spiral CT scan or MRI.
• Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or nodular hyperplasia.
• Patients with hepatitis B or hepatitis C viral infections not associated with liver cancer.

You may not qualify if…

• Patients will be excluded if, upon looking through their medical records, information required for data analysis are missing.

Where it is running

• Stanford University School of Medicine — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.